[
  {
    "ts": null,
    "headline": "U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy速 (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer",
    "summary": "FOSTER CITY, Calif., December 17, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy速 (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.",
    "url": "https://finnhub.io/api/news?id=34c27fa90eda106363ac45f2ae18a4ef4d3448507016074541e456c34492d382",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734442200,
      "headline": "U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy速 (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer",
      "id": 132025811,
      "image": "https://s.yimg.com/ny/api/res/1.2/ebVRWIEDa_wQaY28aedy7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/7ed339f6d17d2ea412d8cd876b41e37b",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., December 17, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy速 (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.",
      "url": "https://finnhub.io/api/news?id=34c27fa90eda106363ac45f2ae18a4ef4d3448507016074541e456c34492d382"
    }
  },
  {
    "ts": null,
    "headline": "Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies",
    "summary": "FOSTER CITY, Calif. & LOS ANGELES, December 17, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.",
    "url": "https://finnhub.io/api/news?id=2b4ac1449265e0c15812782f22701912cc9dc7077006582b640d9a8e3128c92b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436800,
      "headline": "Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies",
      "id": 132025812,
      "image": "https://s.yimg.com/ny/api/res/1.2/EuZ9IhPg0Fcza.pSjQ2Q0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/04a7108fcd129ec85550aebbc178f37c",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif. & LOS ANGELES, December 17, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.",
      "url": "https://finnhub.io/api/news?id=2b4ac1449265e0c15812782f22701912cc9dc7077006582b640d9a8e3128c92b"
    }
  },
  {
    "ts": null,
    "headline": "New HIV prevention drug could reach poorest countries by 2025, says health official",
    "summary": "A new long-acting preventive HIV drug could reach the world's poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday. The ambition is to...",
    "url": "https://finnhub.io/api/news?id=4bd8b4dfdbd7f9a5364c1bfd7391bfe33a573fb0618e81c9dabdc0c6d767bd71",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734426895,
      "headline": "New HIV prevention drug could reach poorest countries by 2025, says health official",
      "id": 132024703,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "A new long-acting preventive HIV drug could reach the world's poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday. The ambition is to...",
      "url": "https://finnhub.io/api/news?id=4bd8b4dfdbd7f9a5364c1bfd7391bfe33a573fb0618e81c9dabdc0c6d767bd71"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration",
    "summary": "By Colin Kellaher Gilead Sciences is working with AI-powered biotechnology company Terray Therapeutics to use artificial intelligence to discover and develop small-molecule therapies across...",
    "url": "https://finnhub.io/api/news?id=9febfea4488f28e22f06481ca94d85f8136b9c61a59448ced3db30b5197608f6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734423200,
      "headline": "Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration",
      "id": 132024064,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Gilead Sciences is working with AI-powered biotechnology company Terray Therapeutics to use artificial intelligence to discover and develop small-molecule therapies across...",
      "url": "https://finnhub.io/api/news?id=9febfea4488f28e22f06481ca94d85f8136b9c61a59448ced3db30b5197608f6"
    }
  }
]